Non-Vitamin K Antagonist Oral Anticoagulants in Pulmonary Embolism: An Overview of Systematic Reviews
- PMID: 32310040
- DOI: 10.2174/1381612826666200506114450
Non-Vitamin K Antagonist Oral Anticoagulants in Pulmonary Embolism: An Overview of Systematic Reviews
Abstract
Background: Anticoagulation in patients with pulmonary embolism.
Objective: To identify how non-vitamin K antagonist oral anticoagulants are associated with multiple outcomes in patients with pulmonary embolism.
Methods: We performed a systematic search of systematic reviews via multiple electronic databases from inception to August 19th, 2019, without language restriction. Two authors independently extracted data and assessed the methodological quality of the included systematic reviews using the ROBIS tool.
Results: We found twelve systematic reviews. Eleven SRs collected their data from randomized clinical trials and one from observational studies. All the included studies were published between 2014 and 2019 in English. The methodological quality of the 12 systematic reviews was low to high. None of the systematic reviews, which are included in our overview of systematic reviews, has evaluated the overall quality of evidence outcome using the Grading of Recommendations Assessments, Development and Evaluation (GRADE) approach.
Conclusion: This is the first effort to summarize evidence about non-vitamin K antagonist oral anticoagulants in an overview of systematic reviews focusing exclusively on patients with pulmonary embolism. The evidence suggests that the non-vitamin K antagonist oral anticoagulants seem to be more effective and safer than a dualdrug approach with LMWH- VKA.
Keywords: Pulmonary embolism; ROBIS tool; anticoagulants; dual-drug; non-vitamin K antagonist oral anticoagulants; systematic review.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months.Prescrire Int. 2013 May;22(138):129-33. Prescrire Int. 2013. PMID: 23819181 Review.
-
Treatment of venous thromboembolism with low-molecular-weight heparin: a synthesis of the evidence published in systematic literature reviews.Respir Med. 2004 May;98(5):376-86. doi: 10.1016/j.rmed.2004.02.017. Respir Med. 2004. PMID: 15139566 Review.
-
Managing pulmonary embolism from presentation to extended treatment.Thromb Res. 2014 Feb;133(2):139-48. doi: 10.1016/j.thromres.2013.09.040. Epub 2013 Oct 14. Thromb Res. 2014. PMID: 24182642 Review.
-
Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer.J Oncol Pharm Pract. 2019 Jan;25(1):52-59. doi: 10.1177/1078155217726158. Epub 2017 Aug 21. J Oncol Pharm Pract. 2019. PMID: 28825375
-
Non-vitamin K antagonist oral anticoagulants for pulmonary embolism: who, where and for how long?Expert Rev Respir Med. 2018 May;12(5):387-402. doi: 10.1080/17476348.2018.1452614. Epub 2018 Mar 26. Expert Rev Respir Med. 2018. PMID: 29542359 Review.
Cited by
-
Oral anticoagulants: a systematic overview of reviews on efficacy and safety, genotyping, self-monitoring, and stakeholder experiences.Syst Rev. 2022 Oct 28;11(1):232. doi: 10.1186/s13643-022-02098-w. Syst Rev. 2022. PMID: 36303235 Free PMC article.
-
Evidence-based perioperative diagnosis and management of pulmonary embolism: A systematic review.Ann Med Surg (Lond). 2022 Apr 28;77:103684. doi: 10.1016/j.amsu.2022.103684. eCollection 2022 May. Ann Med Surg (Lond). 2022. PMID: 35638051 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical